Trilaciclib
| date | publication |
|---|---|
| June 2024 |
Trilaciclib Combined with Sacituzumab Govitecan (SG) In Metastatic Triple-Negative Breast Cancer (mTNBC): Updated Phase 2 Safety and Efficacy Results (Seneviratne, et al.) 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (PDF) |
| December 2023 |
Patients with Metastatic Triple-Negative Breast Cancer Who Receive Trilaciclib Prior to Cytotoxic Chemotherapy Exhibit Improved Survival After Receiving Subsequent Anticancer Therapy (Goel et al.) |
| October 2023 |
Myelosuppression and Healthcare Utilization Among Patients with Chemotherapy-Treated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) with and without Trilaciclib from Community Oncology Practices (Gajra et al.) 2023 American Society of Clinical Oncolgy (ASCO) Quality Care Symposium (PDF) |
| October 2023 |
Assessment Of Hospitalizations and Cytopenia Events Among Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Receiving Chemotherapy with Trilaciclib (Huang et al.) 2023 American Society of Clinical Oncolgy (ASCO) Quality Care Symposium (PDF) |
| October 2023 |
Burden Of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology (Blakely et al.) 2023 American Society of Clinical Oncolgy (ASCO) Quality Care Symposium (PDF) |
| October 2023 |
Patient Characteristics Associated with Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated with Chemotherapy in the Community Oncology Setting (Goldschmidt et al.) 2023 American Society of Clinical Oncolgy (ASCO) Quality Care Symposium (PDF) |
| July 2023 |
Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy |
| July 2023 |
Investigating Potential Immune Mechanisms of Trilaciclib Administered Prior To Chemotherapy In Patients With Metastatic Triple-Negative Breast Cancer |
| June 2023 |
Neoadjuvant Single-Dose Trilaciclib Prior To Combination Chemotherapy in Patients with Early Triple-Negative Breast Cancer: Safety, Efficacy, And Immune Correlate Data from a Phase 2 Study (Force et al.) 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PDF) |
| June 2023 |
Real World Outcomes of Trilaciclib in ES-SCLC (Elijah et al.) 2023 American Society of Clinical Oncology (ASCO) Annual Meeting - eAbstract (PDF) |
| May 2023 |
An Analysis of Patient Characteristics Associated With Myelosuppression Among Small Cell Lung Cancer Patients Treated in US Community Cancer Care Practices (Lopez-Gonzalez et al.) International Society for Pharmacoeconomics and Outcomes Research 2023 (ISPOR) (PDF) |
| May 2023 |
Trilaciclib Combined with Sacituzumab Govitecan (SG) In Metastatic Triple-Negative Breast Cancer (mTNBC): Preliminary Phase 2 Results (Seneviratne et al.) European Society for Medical Oncology (ESMO) Breast Cancer 2023 Annual Congress (ESMO) PDF |
| December 2022 |
Trilaciclib Induces Immune Changes Within the Tumor Microenvironment in Early-Stage Triple-Negative Breast Cancer (Danso et al.) |
| November 2022 |
Burden of Chemotherapy-Induced Myelosuppression Among Patients with ES-SCLC in US Community Oncology Settings |
| November 2022 |
Transient Inhibition of Cyclin-Dependent Kinase 4/6 With Trilaciclib Enhances Inhibitory Receptor Immunotherapy to Improve Antitumor Efficacy (Lu et al.) Society for Immunotherapy of Cancer (SITC) 2022 Annual Conference PDF |
| November 2022 |
Trilaciclib, an Intravenous Cyclin-Dependent Kinase 4/6 Inhibitor, Enhances Antitumor Responses by Modulating T Cells (Ahn et al.) Society for Immunotherapy of Cancer (SITC) 2022 Annual Conference PDF |
| October 2022 |
Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with ES-SCLC in US Community Oncology Settings (Goldschmidt et al.) |
| October 2022 |
Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small Cell Lung Cancer Treated with Trilaciclib: Retrospective Analysis of Florida Community Oncology Practice Data (Hart et al.) |
| September 2022 |
Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: |
| June 2022 |
Impact of Trilaciclib on Multilineage Chemotherapy-Induced Myelosuppression Events in Patients with Extensive-Stage Small Cell Lung Cancer: Post-Hoc Analyses of Data from Randomized Clinical Trials |
| May 2022 |
Economic Impact of Trilaciclib for Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer: Economic Evaluation from The Provider And Patient-Caregiver Perspectives in the United States International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2022 PDF |
| April 2022 |
Treatment Patterns and Burden of Myelosuppression for Patients with Small Cell Lung Cancer: A SEER-Medicare Study Epstein et al., Cancer Treatment and Research Communications |
| March 2022 |
Burden of Myelosuppression Among Patients With Extensive-Stage Small Cell Lung Cancer Treated With Chemotherapy In a Community Oncology Setting National Comprehensive Cancer Network (NCCN) annual conference PDF |
| March 2022 |
Burden of Chemotherapy-Induced Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer: A Retrospective Study of Data From Community Oncology Practices |
| February 2022 |
PRESERVE 3: A Phase II, Randomized, Open-Label Study of Trilaciclib With First-Line, Platinum-Based Chemotherapy and Avelumab Maintenance In Untreated Patients With Locally Advanced or Metastatic Urothelial Carcinoma |
| January 2022 |
Real-world Burden of Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: A Retrospective Analysis of Electronic Medical Data from Community Cancer Care Providers |
| January 2022 |
Budget Impact Analysis of Trilaciclib for Indecreasing the Incidence of Chemotherapy Induced Abraham et al., Journal of Managed Care + Specialty Pharmacy |
| December 2021 |
Trilaciclib and the Economic Value of Multilineage Myeloprotection from Chemotherapy-Induced Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated with First-Line Chemotherapy |
| December 2021 |
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study |
| December 2021 |
Understanding Hematological Adverse Event Management Through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting American Society of Hematology (ASH) (PDF) or Smart Poster (mobile optimized) |
| November 2021 |
Immune Profiling to Investigate Improved Survival in Patients with Metastatic Triple-Negative Breast Cancer Receiving Trilaciclib Prior to Chemotherapy |
| October 2021 |
Real-World Burden of Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting |
| September 2021 |
PRESERVE 1: A Phase III, Randomized, Double-Blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer European Society of Medical Oncology (ESMO) (PDF) or Smart Poster (mobile optimized) |
| August 2021 |
Trilaciclib Prior to Chemotherapy Reduces the Usage of Supportive Care Interventions for Chemotherapy-Induced Myelosuppression in Patients with Small Cell Lung Cancer: Pooled Analysis of Three Randomized Phase 2 Trials |
| July 2021 |
Myeloprotective effects of trilaciclib among patients with small cell lung cancer at increased risk of chemotherapy-induced myelosuppression: Pooled results from three phase 2, randomized, double-Blind, placebo-controlled studies |
| July 2021 |
Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer |
| June 2021 |
Effects of Trilaciclib Prior to Chemotherapy ± Atezolizumab on T-cell Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer (eAbstract) |
| June 2021 |
PRESERVE 2: A Phase 3, Randomized, Double-Blind Trial of Trilaciclib versus Placebo in Patients Receiving First- or Second-Line Gemcitabine and Carboplatin for Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer American Society of Clinical Oncology (ASCO) (PDF) or Smart Poster (mobile optimized) |
| May 2021 |
Cost-Benefit Analysis of Trilaciclib for the Prevention of Chemotherapy-Induced Myelosuppression in Extensive-Stage Small Cell Lung Cancer International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (PDF) or Smart Poster (mobile optimized) |
| May 2021 |
Trends in Prevalence, Treatment Patterns, Myelosuppression, and Burden on the Health Care System Among Patients with Small Cell Lung Cancer: A SEER-Medicare Analysis International Society for Pharmacoeconomics and Outcomes Research (ISPOR) (PDF) or Smart Poster (mobile optimized) |
| April 2021 |
A Budget Impact Assessment of Trilaciclib for Decreasing the Incidence of Chemotherapy-Induced Myelosuppression in Adult Patients with Extensive-Stage Small Cell Lung Cancer 2021 Academy of Managed Care Pharmacy (ACMP) meeting: Poster (PDF) or Smart Poster (mobile optimized) |
| April 2021 |
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase 2 Randomized, Double-Blind, Placebo Controlled Studies |
| Feb 2021 |
Cancer Patients' Perspectives and Experiences of Chemotherapy-Induced Myelosuppression and Its Impact on Daily Life. |
| Feb 2021 |
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer Li, C., Hart, L., Owonikoko, T.K. et al., Cancer Chemotherapy and Pharmacology |
| Dec 2020 |
Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: a multicentre, randomised, double‐blind, placebo‐controlled phase II trial |
| Dec 2020 |
Trilaciclib improves overall survival when given with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: Final analysis of a randomized phase 2 trial 2020 San Antonio Breast Cancer Symposium (SABCS) Spotlight Poster Discussion: O’Shaugnessy et al., Poster #PD1-06 (PDF) or Smart Poster (mobile optimized) |
| Nov 2020 |
Myelopreservation with trilaciclib in patients receiving topotecan for small cell lung cancer: Results from a randomized, double-blind, placebo-controlled Phase II study |
| Oct 2020 |
Trilaciclib reduces the need for growth factors and red blood cell transfusions to manage chemotherapy-induced myelosuppression |
| Oct 2020 |
Trilaciclib has myelopreservation benefits in patients with small cell lung cancer treated with chemotherapy, irrespective of age North America Conference on Lung Cancer (NACLC) Poster: Beck et. al., Poster# MO01.40 (PDF) or Smart Poster (mobile optimized) |
| Oct 2020 |
Using an exploratory composite endpoint to evaluate the myelopreservation benefits of trilaciclib in patients with small cell lung cancer North America Conference on Lung Cancer (NACLC) Poster: Subramanian et. al., Poster# MO01.41 (PDF) or Smart Poster (mobile optimized) |
| Oct 2020 |
Myelopreservation with trilaciclib regardless of risk of chemotherapy-induced febrile neutropenia and/or anemia/red blood cell transfusions North America Conference on Lung Cancer (NACLC) Poster: Hussein et al., Poster# MO01.42 (PDF) or Smart Poster (mobile optimized) |
| Oct 2020 |
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy |
| July 2020 |
Patient burden and real-world management of chemotherapy-induced myelosuppression: Results from an online survey of patients with solid tumors |
| May 2020 |
Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer |
| May 2020 | Impact of chemotherapy-induced myelosuppression on daily living: results of a U.S. online survey of patients with cancer ISPOR 2020 Congress Poster: Epstein et al., Poster# PCN333 (PDF) or Smart Poster (mobile optimized) |
| Sep 2019 | Trilaciclib decreases myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy plus atezolizumab ESMO 2019 Congress Poster: Daniel et al., Abstract #1742PD (pdf) or SmartPoster (mobile optimized) |
| Sep 2019 | Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial Tan et al., Lancet Oncology |
| Sep 2019 | Trilaciclib improves overall survival when given with gemcitabine/carboplatin (GCb) in patients with metastatic triple negative breast cancer (mTNBC) in a randomized, open-label, Phase 2 trial ESMO 2019 Congress Presentation: O’Shaugnessy et al., Oral Presentation (pdf) |
| Aug 2019 | Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small cell lung cancer receiving 1st-line chemotherapy: a Phase 1b/randomized Phase 2 trial Weiss et al., Annals of Oncology |
| Jun 2019 | Positive effects of trilaciclib on patient myelosuppression-related symptoms and functioning: results from three phase 2 randomized, double-blind, placebo-controlled small cell lung cancer trials MASCC Oral Presentation: Weiss et al., Abstract #MASCC9-0845 (pdf) |
| Jun 2019 | Effect of trilaciclib, a CDK 4/6 inhibitor, on myelosuppression in patients with previously treated extensive-stage small cell lung cancer ASCO Oral Presentation: Hart et al., Abstract #8505 (pdf) |
| Dec 2018 | Trilaciclib, a CDK4/6 inhibitor, dosed with Gemcitabine, Carboplatin in metastatic triple negative breast cancer (mTNBC) patients: Preliminary Phase 2 results SABCS Poster: O'Shaughnessy et al., Abstract #1191 (pdf) |
| Nov 2018 | Trilaciclib, a CDK4/6 inhibitor, does not impair the efficacy of chemotherapy in CDK4/6-dependent tumor models EORTC-NCI-AACR Symposium Poster: Sorrentino et al., Abstract #377 (pdf) |
| Oct 2018 | Trilaciclib decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving 1st line chemotherapy ESMO 2018 Congress Poster: Dragnev et al., Abstract #1666PD (pdf) |
| Oct 2018 | Trilaciclib preserves and enhances immune system function in extensive-stage small cell lung cancer (SCLC) patients receiving first-line chemotherapy ESMO 2018 Congress Poster: Sorrentino et al., Abstract #1671P (pdf) |
| Apr 2018 | Transient exposure to trilaciclib, a CDK4/6 inhibitor, modulates gene expression in tumor immune infiltrates and promotes a pro-inflammatory tumor microenvironment AACR Annual Meeting Poster: Lai et al., Abstract #1752 (pdf) |
| Nov 2017 | CDK4/6 inhibition augments anti-tumor immunity by enhancing T cell activation Deng et al., Cancer Discovery |
| Jun 2017 | Trilaciclib (G1T28): a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin (EP) for extensive stage small cell lung cancer (ES-SCLC): Phase 1b results ASCO Annual Meeting Poster: Rocha Lima et al., Abstract #8568 (pdf) |
| Apr 2017 | Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion He et al., Science Translational Medicine |
| Apr 2017 | Trilaciclib (G1T28), a CDK4/6 inhibitor, enhances the efficacy of combination chemotherapy and immune checkpoint inhibitor treatment in preclinical models AACR Annual Meeting Poster: Sorrentino et al., Abstract #5628 (pdf) |
| Dec 2016 | Trilaciclib (G1T28), a cyclin dependent kinase 4/6 inhibitor, in combination with topotecan for previously treated small cell lung cancer: preliminary results WCLC Annual Meeting Poster: Hart et al., Abstract #5213 (pdf) |
| Nov 2016 | Trilaciclib (G1T28), a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy EORTC-NCI-AACR Symposium Poster: Roberts et al., Abstract #439 (pdf) |
| May 2016 | Preclinical characterization of G1T28: a novel CDK4/6 inhibitor for reduction of chemotherapy-induced myelosuppression Bisi et al., Molecular Cancer Therapeutics (pdf) |
| Apr 2016 | G1T28, a cyclin dependent kinase 4/6 inhibitor, in combination with etoposide and carboplatin for extensive stage small cell lung cancer (ES-SCLC): preliminary results AACR Annual Meeting Poster: Rocha Lima et al., Abstract #CT151 (pdf) |
| May 2015 | Evaluation of targeted bone marrow arrest by G1T28, a CDK4/6 inhibitor in clinical development to reduce chemotherapy-induced myelosuppression ASCO Annual Meeting Poster: Roberts et al., Abstract #2529 (pdf) |
| May 2015 | First-in-human phase 1a safety, PK, and PD study of the CDK4/6 inhibitor G1T28 (G1T28-1-01) ASCO Annual Meeting Poster: Tiessen et al., Abstract #2527 (pdf) |
| Apr 2015 | Pre-clinical characterization of G1T28, a novel CDK4/6 inhibitor for protection of bone marrow from cytotoxic chemotherapies AACR Annual Meeting Poster: Bisi et al., Abstract #1784 (pdf) |